Biodexa Pharmaceuticals (BDRX) Capital Expenditures (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) reported Capital Expenditures of -$38706.6 for Q4 2022, up 84.81% on a YoY basis from -$20944.3 in Q4 2021, and up 5.16% sequentially from -$40812.0 in Q3 2022.
Biodexa Pharmaceuticals (BDRX) Capital Expenditures (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 8 years of Capital Expenditures data on file, last reported at -$38706.6 in Q4 2022.
- For the quarter ending Q4 2022, Capital Expenditures rose 84.81% year-over-year to -$38706.6; the trailing twelve-month figure through Dec 2022 stood at -$596905.2 (up 20.09% YoY), and the FY2025 full-year result was -$2637.0, up 77.17% from the prior year.
- Capital Expenditures rose to -$38706.6 in Q4 2022, from -$40812.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of -$25714.5 in Q4 2019 to a low of -$262612.6 in Q3 2021.
- A 4-year average of -$121745.1 and a median of -$112076.0 in 2020 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 357.02% in 2020 and soared 84.81% in 2022, its largest moves.
- Tracing BDRX's Capital Expenditures over 4 years: stood at -$25714.5 in 2019, then sank by 357.02% to -$117520.1 in 2020, then sank by 116.79% to -$254774.0 in 2021, then surged by 84.81% to -$38706.6 in 2022.
- Business Quant data shows BDRX's Capital Expenditures at -$38706.6 in Q4 2022, -$40812.0 in Q3 2022, and -$254774.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -38,706.63 |
| Dec 31, 2022 | -38,706.63 |
| Sep 14, 2022 | -40,811.96 |
| Sep 14, 2022 | -40,811.96 |
| Dec 31, 2021 | -254,774.00 |
| Dec 31, 2021 | -254,774.00 |
| Sep 17, 2021 | -262,612.65 |
| Sep 17, 2021 | -262,612.65 |
| Dec 31, 2020 | -117,520.14 |
| Dec 31, 2020 | -117,520.14 |
| Sep 10, 2020 | -112,075.95 |
| Sep 10, 2020 | -112,075.95 |
| Dec 31, 2019 | -25,714.50 |
| Dec 31, 2019 | -25,714.50 |
| Dec 31, 2016 | -1.67 Mn |
| Dec 31, 2016 | -1.67 Mn |
| Dec 31, 2015 | -1.40 Mn |
| Dec 31, 2015 | -1.40 Mn |
| Dec 31, 2014 | -1.63 Mn |
| Dec 31, 2014 | -1.63 Mn |